Peeters M, Gueye A, Mboup S, Bibollet-Ruche F, Ekaza E, Mulanga C, Ouedrago R, Gandji R, Mpele P, Dibanga G, Koumare B, Saidou M, Esu-Williams E, Lombart J P, Badombena W, Luo N, Vanden Haesevelde M, Delaporte E
Laboratoire Retrovirus, ORSTOM, Montpellier, France.
AIDS. 1997 Mar 15;11(4):493-8. doi: 10.1097/00002030-199704000-00013.
To determine to what extent HIV-1 group O strains are present in different African countries.
A total of 14,682 samples of sera from a range of patients from 12 different African countries were tested. All the sera were tested with an enzyme-linked immunosorbent assay (ELISA) using a combination of V3 peptides from ANT-70 and MVP-5180. Samples reactive in ELISA were retested in a line immunoassay (LIA-O). Samples reactive in ELISA were also retested with an in-house Western blot to determine the presence of antibodies to gp120 of HIV-1 ANT-70. Polymerase chain reaction was performed on HIV-1 group O and group O indeterminate sera.
Of all the sera samples tested, only 19 sera had antibodies to group O V3 peptides exclusively and 46 were indeterminate for group O infection in LIA-O. The highest prevalence of HIV-1 group O infection among HIV-positive sera was observed in Cameroon (2.1%) and neighbouring countries, 1.1% in Nigeria and 0.9% in Gabon. The lowest rates were seen in west Africa: 0.07% in Senegal, 0.14% in Togo, 0.16% in Chad and 0.3% in Niger. Group O sera were observed in almost all the population categories tested. The ANT-70 V3 peptide in LIA-O was reactive with all of the sera considered to be HIV-1 group O antibody positive by LIA, versus 78.9% for the MVP-5180 peptide. Thirteen out of 19 group O samples of sera were tested in PCR. Eight samples were identified as group O by specific group O pol and/or V3 primers; in the remaining five samples no HIV RNA could be detected. Of the indeterminate sera samples, two were identified as group O.
In eight of the 12 countries tested, antibodies to group O viruses were identified. Numbers of HIV-1 group O viruses are low. Their presence is not restricted to Cameroon and neighbouring countries but can also be found in west and south-east Africa.
确定不同非洲国家中HIV-1 O组毒株的存在程度。
对来自12个不同非洲国家的一系列患者的总共14682份血清样本进行检测。所有血清均使用来自ANT-70和MVP-5180的V3肽组合通过酶联免疫吸附测定(ELISA)进行检测。ELISA反应性样本在条带免疫测定(LIA-O)中重新检测。ELISA反应性样本也用内部蛋白质印迹法重新检测,以确定是否存在针对HIV-1 ANT-70的gp120抗体。对HIV-1 O组和O组不确定血清进行聚合酶链反应。
在所有检测的血清样本中,仅19份血清仅具有针对O组V3肽的抗体,46份在LIA-O中O组感染不确定。在喀麦隆(2.1%)及周边国家观察到HIV-1 O组感染在HIV阳性血清中的患病率最高,尼日利亚为1.1%,加蓬为0.9%。在西非观察到的感染率最低:塞内加尔为0.07%,多哥为0.14%,乍得为0.16%,尼日尔为0.3%。在几乎所有检测的人群类别中均观察到O组血清。LIA-O中的ANT-70 V3肽与所有被LIA认为是HIV-1 O组抗体阳性的血清反应,而MVP-5180肽的反应率为78.9%。19份O组血清样本中的13份进行了PCR检测。8份样本通过特定的O组pol和/或V3引物被鉴定为O组;在其余5份样本中未检测到HIV RNA。在不确定血清样本中,2份被鉴定为O组。
在检测的12个国家中的8个国家中鉴定出了针对O组病毒的抗体。HIV-1 O组病毒数量较少。它们的存在不仅限于喀麦隆及周边国家,在西非和东南部非洲也能发现。